Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate if up to two injections of plerixafor represent
a safe and effective strategy to mobilize adequate numbers of CD34+ hematopoietic stem
progenitor cells (HSPC) for autologous hematopoietic cell transplantation (HCT) in sickle
cell disease (SCD) patients